Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and related conditions. Its lead product candidate, oral (Z)-endoxifen, a selective estrogen receptor modulator, targets prevention and treatment of estrogen receptor-positive breast cancer. The company advances drug candidates through clinical trials, leveraging third-party manufacturing and research partnerships, and aims to address unmet medical needs in oncology with patented therapies for a global patient base.
This description was generated via AI from an annual report. Updated about 1 year ago.